Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02754856 2024-10-09

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Phase 1 Completed

24 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT03946800 2024-10-02

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Phase 1 Completed

61 enrolled

Tumor-Agnostic

Neoplasms

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

114 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03421353 2024-08-21

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Phase 1 Completed

76 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT03238027 2024-05-17

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Phase 1 Completed

45 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02301130 2024-04-25

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Phase 1 Completed

64 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03610061 2024-04-12

RaDD

Phase 1 Completed

34 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02762006 2024-03-18

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Phase 1 Completed

29 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Phase 1 Completed

72 enrolled 23 charts

Other solid neoplasm

Solid Tumor

NCT02793466 2023-09-22

Durvalumab in Pediatric and Adolescent Patients

Phase 1 Completed

15 enrolled

CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT03452332 2023-09-13

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Phase 1 Completed

20 enrolled

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT02649686 2023-08-04

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Phase 1 Completed

15 enrolled

Breast

Breast Neoplasms

NCT02503774 2023-07-11

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Phase 1 Completed

192 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02740985 2023-05-26

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Phase 1 Completed

313 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Colorectal Neoplasms

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Phase 1 Completed

27 enrolled

Thoracic

High-Risk Resectable NSCLC

NCT03889275 2023-02-21

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

Phase 1 Completed

39 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01975831 2022-10-12

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1 Completed

104 enrolled 23 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03773666 2022-09-13

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Phase 1 Completed

12 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04261075 2022-08-15

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Phase 1 Completed

57 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03122496 2022-06-08

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Phase 1 Completed

13 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02088112 2022-04-04

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Phase 1 Completed

56 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03056599 2021-09-24

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Phase 1 Completed

23 enrolled

Sarcoma

NCT02777710 2021-09-05

MEDIPLEX

Phase 1 Completed

48 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Phase 1 Completed

26 enrolled

Advanced Malignancy

NCT03144778 2021-03-18

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Phase 1 Completed

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Phase 1 Completed

269 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

NCT02572687 2021-01-20

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Phase 1 Completed

85 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Neoplasm Metastasis, Stomach Neoplasms

NCT02900157 2021-01-14

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

Phase 1 Completed

42 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03544125 2020-11-20

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Phase 1 Completed

3 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03430518 2020-08-05